ArticleBMC cancer2025
Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Efficacy and safety of low-molecular-weight heparin or rivaroxaban combined with immunotherapy and chemotherapy in the treatment of advanced nonsmall cell lung cancer: a prospective, randomized, controlled clinical study.Cancer immunology, immunotherapy : CII · 2025Trial
- Causal relationship between immune factors and Guillain-Barré syndrome: A Mendelian randomization study.Medicine · 2026Article
- LncRNA DLX6-AS1 promotes necroptosis through PI3K/AKT/mTOR signaling pathway in myocardial ischemia/reperfusion injury mice.Scientific reports · 2026Article
- Helicobacter pylori promote M1 macrophage polarization via JAK3-mediated activation of the SOCS3/IL2RA axis to suppress host immunity.Archives of microbiology · 2026Article
- Transcriptomic analysis of lncRNA-miRNA-mRNA competing endogenous RNA regulatory networks in radiation-induced mouse thymic degeneration.Immunologic research · 2026Article
- Development and validation of a novel T cell exhaustion-related signature to predict prognosis in patients with breast cancer.Discover oncology · 2026Article
- Pan-cancer 8q24 amplification predicts primary immunotherapy resistance and therapeutic vulnerabilities.iScience · 2026Article
- Development and validation of a novel prognostic and for osteosarcoma patients utilizing multiple organelle related genes.Discover oncology · 2026Article
- TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response.Hereditas · 2026Article
- VAV2-associated ncRNA network in the focal adhesion pathway is dysregulated in laryngeal squamous cell carcinoma.Discover oncology · 2026Article
- Single-cell N4-acetylcytidine regulatory landscape identifies ARIH1 as a ferroptosis-suppressive oncogenic driver in lung adenocarcinoma.Respiratory research · 2026Article
- Mitotic catastrophe-related six-gene signature predicts prognosis, tumor immune landscape, and therapeutic response in lung adenocarcinoma.BMC medical genomics · 2026Article
- Integrated pan cancer analysis with breast cancer validation identifies SEC13 homolog as prognostic biomarker and immunotherapy target.Scientific reports · 2026Article
- Signal Transduction and Transcription Activator 1 in Pan-Cancer: Prognostic and Immunological Value.Clinical and experimental medicine · 2026Article
- Multi-omics integration reveals pan-cancer roles of ZIC family genes in prognosis, immune microenvironment remodeling, and therapeutic vulnerability.Discover oncology · 2026Article
- A pan-cancer analysis of TMEM132A in human tumors.Discover oncology · 2026Article
- Transcriptomics and network pharmacology reveal that baicalin alleviates acute lung injury induced by H1N1 via targeting STAT1.Archives of microbiology · 2026Article
- Comprehensive Bioinformatic Analysis of TONSL Expression in Pan-Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- miR-155-5p promotes osteosarcoma progression and cisplatin resistance by targeting the SOCS1/STAT1/c-Fos signaling axis.Discover oncology · 2026Article
- The MAD2L1-FOXM1 axis negatively regulates CD4⁺ T cell and macrophages infiltration in lung adenocarcinoma.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The recent elucidation of disulfidptosis, a unique form of cell death, has opened new paths for the development of targeted cancer therapies. However, a thorough examination of disulfidptosis-related genes (DRGs) across various cancer types has been lacking. Our extensive analysis of DRGs through genomic, transcriptional, and immune profiling has yielded substantial insights. Utilizing The Cancer Genome Atlas (TCGA), we have identified key changes in gene expression, including alterations in copy number and DNA methylation, and evaluated their impact on cancer prognosis. We constructed a disulfidptosis-related signature (DFRS) using LASSO regression and multivariate Cox regression analysis, which demonstrated a strong prognostic connection across diverse cancer types. The DFRS score is linked with poorer clinical outcomes, reflects the immune characteristics of the tumor microenvironment (TME), and predicts responsiveness to immunotherapy and other treatments. Notably, the DFRS score interacts with critical oncogenic pathways, highlighting the potential benefits of targeting disulfidptosis in cancer treatment. Our findings underscore the critical influence of disulfidptosis on cancer prognosis and therapeutic response, offering meaningful clinical insights.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.